Filippo Pietrantonio, MD, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, discusses data from the Phase II INFINTY trial (NCT04817826) of tremelimumab and durvalumab in patients with MSI-high gastric/gastroesophageal junction cancer (G/GEJC). Patients were divided into two cohorts, where they received the investigational regimen as neoadjuvant or definitive therapy. Neoadjuvant tremelimumab and durvalumab demonstrated encouraging pathologic complete response rates and was additionally well tolerated, where quality of life was not negatively impacted. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.